Legend Strategy International (01355.HK) Hot Market Trend Analysis

Legend Strategy International (01355.HK), formerly known as Legend Strategy International Holdings Group, originally engaged in tourism and accommodation consulting. It has recently become a market hotspot due to its strategic transformation [0]. On December 23, 2025, the company announced the acquisition of a 37.5% stake in Baisheng Biology, a synthetic biology infrastructure provider, for HK$22 million, and plans to rename itself “Biosystems Engineering Limited” to focus on synthetic biology business [1][2][3][4]. According to internal analysis data, the company’s current market capitalization is HK$143.2 million, and it recorded a net loss of HK$37.81 million in the previous fiscal year ending June 30, 2025 [0].

1. Track Switch Logic
   : The company is shifting from the traditional service industry to the synthetic biology track, attempting to break through in business by leveraging the development potential of this field. This transformation decision is the core driver behind it becoming a hot stock.
2. Comparison Between Market Capitalization and Acquisition Scale
   : The HK$22 million acquisition amount accounts for a relatively high proportion of Legend Strategy International’s market capitalization of only HK$1.4 billion, reflecting the company’s determination to transform, but it may also bring certain financial pressure.

• Risks
  : The original business continues to lose money, and the execution effect of the transformation strategy is uncertain; the synthetic biology industry has high technical barriers and fierce competition, so it is questionable whether the company can quickly establish a competitive advantage; currently, there is a lack of latest price data, making it impossible to evaluate short-term market reactions [0].
• Opportunities
  : As an emerging track, synthetic biology has broad development prospects; if the transformation is successful, the company’s business value is expected to be restructured.

Legend Strategy International (01355.HK) has become a hot stock due to its plan to acquire a stake in Baisheng Biology and transition to synthetic biology business. The company’s original business losses, transformation effect, and industry competition are the main risk points; attention should be paid to the progress of the transformation and the subsequent performance of the synthetic biology business.

The event analysis is based on the acquisition announcement on December 23, 2025 and the hot market trends on December 29, 2025 [1][2][3][4].